Meta-analysis of the efficacy and safety of bispecific antibodies in immune therapy for lung cancer.

This work evaluates the efficacy and safety of bispecific antibod-ies (BsAbs) in lung cancer immunotherapy through a meta-analysis, providing more comprehensive evidence for their clinical application. A systematic search was conducted in PubMed, Embase, Cochrane Library, and various Chinese da-tabases to identify eligible randomized controlled trials and quasi-randomized controlled trials. Clinical data on bispecific antibody therapy for lung cancer were collected. The primary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and the incidence of im-mune-related adverse events (irAEs). Data analysis was performed using Rev-Man 5.3 software, with fixed-effect or random-effects models. Nine studies were included, with a total sample size of 588 patients. The meta-analysis revealed no statistically significant differences between the bispecific antibody group and the traditional treatment group in ORR, OS and PFS, with combined effect sizes of odds ratio (OR)=1.31 and 95% confidence interval (CI)=0.98-1.76, OR=1.36 and 95%CI=0.99-1.87 and OR=1.07 and 95%CI=0.80-1.43, respec-tively (p 0.07, 0.06, and 0.64, respectively). However, the incidence of irAEs was significantly lower in the bispecific antibody group (OR = 1.56; p = 0.0007), indicating a reduction in such events. Bispecific antibodies demonstrate good safety in lung cancer immunotherapy, particularly in reducing irAEs. Despite some improvements in efficacy (e.g., ORR and OS), BsAbs do not demonstrate a significant superiority over conventional treatments.